Latest news with #MatthewPeterson
CTV News
3 days ago
- Sport
- CTV News
Demski has two touchdown catches in Blue Bombers' 34-20 victory over Lions
Blue Bombers quarterback Chris Streveler (17) throws to Matthew Peterson (22) as he's pressured by BC Lions lineman Jonah Tavai (99) during first-half CFL action in Winnipeg on Thursday, June 12, 2025. THE CANADIAN PRESS/John Woods WINNIPEG — If someone had told Matthew Peterson he'd carry the ball for 130 yards and a touchdown in his CFL debut, the Blue Bombers running back was candid in what his response would have been. 'I'm confident, you know. I would have said, 'You're damn right,'" he said with a smile, repeating the line for greater effect. "No, I'm glad I could just come out here and just do my thing and make sure that the offence still flows.' Winnipeg defeated the B.C. Lions 34-20 in their season opener on Thursday without starting quarterback Zach Collaros and star running back Brady Oliveira. Collaros was serving a one-game suspension for failing to respond to an off-season drug-testing request. He was replaced by Chris Streveler, who threw two of his three touchdown passes to Nic Demski. Streveler completed 15 of 24 pass attempts for 246 yards and one interception in front of a sellout of 32,343 at Princess Auto Stadium. 'Just guys leaning on each other and making their plays,' Streveler said. 'Matt (Peterson) stepping up, having a great game. Guys making plays when the ball comes their way. And the great thing is, there's still improvements to be made.' Winnipeg opened the game with a four-play, 80-yard touchdown drive. Oliveira, the CFL's reigning most outstanding player and top Canadian, burst out of the gates for a 43-yard gain, the longest carry of his career. Streveler followed up with a 20-yard TD pass to Demski in the end zone at 2:29, marking his 72nd consecutive game with at least one reception. Oliveira went to the locker room after the score. The Bombers (1-0) announced he wouldn't return because of an upper-body injury. There was no update after the game. B.C. quarterback Nathan Rourke left the game midway through the fourth quarter after an apparent injury. He was 12 of 27 passing for 249 yards with one TD and one interception. He also ran two yards for a score. Rourke was replaced by Jeremiah Masoli as the Lions fell to 1-1. 'I'm not sure exactly what it is,' Rourke told reporters after the game of the possible injury to his midsection. 'I won't speculate, but it was affecting the way I was throwing it. I couldn't throw it, so I thought it was better for the team if I took myself out at that point because I wasn't able to generate enough power on the ball.' He said he's optimistic he'll be ready to go when the Lions host the Bombers in a June 21 rematch. Keric Wheatfall had Winnipeg's other TD reception, finishing with five catches for 127 yards. Sergio Castillo booted field goals from 49 and 50 yards for Winnipeg, but missed from 47 yards out. He made three of his four convert attempts and the Bombers also picked up a point off a punt single. Keon Hatcher caught a 77-yard TD pass for the Lions and finished with four catches for 150 yards. Sean Whyte hit field goals from 21 and 37 yards and connected on two converts. The Bombers led 10-3 after the first quarter, 18-10 at halftime and 28-20 heading into the fourth. 'I believe in our guys' ability to fight and make plays down the stretch,' Lions head coach Buck Pierce said. "They've got to understand it's a game of opportunities and we didn't start the way that we wanted to start the game or the first half, for that matter.' After Demski's opening touchdown, the Bombers boosted their lead thanks to a turnover. Defensive back Marquise Bridges intercepted a tipped Rourke pass attempt, leading to Castillo's 49-yarder and a 10-0 lead at 8:39. Rourke, who was pressured by Winnipeg's defence all game, ran for 36 yards to get his team to Winnipeg's 13-yard line but the Lions settled for Whyte's 21-yarder at 10:23. The five-foot-nine 208-pound Peterson ran 38 yards for his touchdown at 7:25 of the second quarter. Winnipeg got the punt single four minutes later to go up 18-3. Rourke ran two yards for a score with nine seconds remaining in the half. After Wheatfall's 30-yard TD catch at 7:57 of the third quarter, Hatcher made an over-the-shoulder grab for his 77-yard score. Whyte's 37-yard field goal squeezed the score to 28-20 at 11:28. Demski hauled in a four-yard TD catch in the corner of the end zone at 3:48 of the fourth. Winnipeg got another turnover off a fumbled B.C. kickoff return, but Castillo went wide on his field-goal attempt and the ball was run out. This report by The Canadian Press was first published June 12, 2025. Judy Owen, The Canadian Press
Winnipeg Free Press
12-05-2025
- Sport
- Winnipeg Free Press
Putting his best foot forward
Matthew Peterson was in Kananaskis, Alta., for his honeymoon last month when his alarm went off at 9:30 a.m. When he opened his phone, his Instagram had blown up, and he had a few missed phone calls. One was from his agent. The other was from Winnipeg Blue Bombers head coach Mike O'Shea. 'So then I got the (voicemail) and I listened to it right away, and I was like, 'Something big just happened,'' Peterson recalled. Ruth Bonneville / Free Press Running back Matthew Peterson takes a hand off from quarterback Zach Collaros at Winnipeg Blue Bombers training camp Monday. His wife, Kalie, confused, asked what had happened. Peterson told her he had been traded to Winnipeg. The 24-year-old running back was one of the key pieces in a deal on the morning of the CFL draft, which included Winnipeg and Hamilton swapping picks in the CFL and global drafts, respectively, while the Bombers received Peterson and the Ti-Cats received Canadian defensive lineman Kyle Samson. Peterson was drafted by Hamilton in the fourth round, 36th overall of the 2024 draft, but never played a down for the Tabbies. 'I was never upset about getting traded,' he said. 'To be quite honest, any opportunity to get out and play football, whether it's here or anywhere else, that's a great opportunity for me. So, I was happy.' There is an opportunity for the young rusher with the Blue and Gold. While Brady Oliveira remains the bellwether and fellow newcomer Peyton Logan appears locked in as the change-of-pace option, Peterson is vying to earn a roster spot as a Canadian depth option. 'I was happy, because then that gives me another opportunity to play ball, and not just play ball, but play ball for Winnipeg,' he added. 'And come out here in Winnipeg, experience the coaching staff, experience the players, and have that playoff experience from the vets that I can learn from. Honestly, it was a joy to me.' Peterson was a standout at the University of Alberta. The 5-10, 210-pound back spent five years with the Golden Bears, rushing 477 times for 3,032 yards and nine touchdowns, while adding 62 receptions for 583 yards for three majors. MIKE DEAL / FREE PRESS Running back Matthew Peterson was added to the Winnipeg Blue Bombers roster the morning of the CFL draft. Last year, he gave the Manitoba Bisons hell, in particular, rushing 39 times for 320 yards in two contests. A north-south runner at his core, Peterson can surprise with his quick foot and breakaway speed. He models his game after pro football Hall of Famer Earl Campbell, noting he loves the relentlessness and power he demonstrated throughout his legendary career. It's a fitting role model, as Campbell was regarded for a punishing style that was powered by his massive legs. Peterson might give Campbell a run for his money in that area. His best squat was 730 pounds for two reps. 'He's way thicker than I remember,' said head coach Mike O'Shea, who watched Peterson anytime he visited the Bisons. 'Like he's,' O'Shea paused, 'he's a thick athlete.' There's another running back who's caught Peterson's eye since arriving in Winnipeg. 'I've been looking at Brady Oliveira,' he said. 'He's the best in the league for a reason, so I kind of just take little cues that he has, and I kind of just try to mould them to me. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. 'One of the things I've noticed that he's really good at is patience, and that's something that a running back needs — to be able to hold that backfield, and then when you see the hole, you hit it. That's something that I've noticed, that I'm trying to apply to my game while I'm here being a professional. I think it's something big to be able to stay patient, allow your blocks to develop and hit it right after.' Ruth Bonneville / Free Press Running back Matthew Peterson (centre) spent five years with the University of Alberta Golden Bears, rushing 477 times for 3,032 yards and nine touchdowns, while adding 62 receptions for 583 yards for three majors. One thing Peterson doesn't shy away from is competition. He's embraced fighting for extra reps in practice, which should come easily to him after owning the lion's share of touches in Alberta's backfield last season despite the presence of another productive running back in Ope Oshinubi. 'Competition is competition. It doesn't matter if it's a wide receiver and I'm having to compete against him, it doesn't matter if it's a defensive back or a linebacker and having to compete against them. Competition is competition, regardless. And I'm here for it, and I love competition,' he said. 'I'm just gonna put my best foot forward and try to fulfill my role anyway I can. And not just that, but put my best foot forward, and my mentals, my physicals, and just trying to do what I can do, and be the best I can possibly be. And I think that's good enough.' Joshua Frey-SamReporter Josh Frey-Sam reports on sports and business at the Free Press. Josh got his start at the paper in 2022, just weeks after graduating from the Creative Communications program at Red River College. He reports primarily on amateur teams and athletes in sports. Read more about Josh. Every piece of reporting Josh produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Global News
29-04-2025
- Sport
- Global News
Bombers trade players, picks with Hamilton
The Winnipeg Blue Bombers have traded players and draft picks with the Hamilton Tiger-Cats. The club announced Tuesday morning that it has acquired running back Matthew Peterson, along with the second pick in the first round of the global draft and the 39th overall pick in the CFL draft. Heading to Hamilton are defensive lineman Kyle Samson, the eighth pick in the first round of the global draft and the 36th overall CFL draft pick. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Peterson, 24, was a standout at the University of Alberta and attended training camp with the Tiger-Cats. Samson, also 24, spent time on the Bombers' practice roster last season, making his pro debut in the Grey Cup game.
Yahoo
21-03-2025
- Business
- Yahoo
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the 'Company'), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. In 2024, Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing buntanetap's ability to improve cognition in AD and PD patients, as well as motor function in PD patients. Building on this success, the FDA cleared Annovis to proceed with a pivotal Phase 3 trial in early AD, which was launched at the start of 2025. The Company also participated in multiple scientific and investor conferences, announced new publications in peer-reviewed journals, expanded its patent portfolio, and added accomplished professionals to its growing team. 'The last year was filled with extraordinary achievements for our company, and we are pleased with our continued momentum into 2025,' said Maria Maccecchini, Ph.D., Founder and CEO of Annovis. 'We are deeply grateful to everyone who has supported and believed in our mission. As we move ahead, our focus remains on generating robust data for buntanetap and advancing its path to the patients who need it most.' Clinical progress In October 2024, the FDA granted clearance to proceed with a pivotal Phase 3 study for early AD, based on Phase 2/3 clinical data demonstrating symptomatic improvement in the subgroup of early AD patients. In February 2025, Annovis launched the pivotal Phase 3 AD study, which includes a 6-month data readout focused on buntanetap's symptomatic effects followed by an additional 12-month assessment to evaluate its potential disease-modifying response. The symptomatic data is anticipated in mid-2026, followed by the disease-modifying data in mid-2027, with both expected to support their respective New Drug Applications (NDAs). Business highlights In October 2024, Annovis appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist. In this role, Dr. Peterson ensures the medical, ethical, and scientific integrity of Annovis' clinical trials, overseeing their initiation, execution, reporting, and successful completion. In October and November 2024, Annovis' leadership participated in key scientific conferences in the neurodegenerative disease space. At the 7th Clinical Trials on Alzheimer's Disease (CTAD) conference, Annovis presented two posters highlighting findings from its Phase 2/3 AD trial and related biomarker data. Additionally, Annovis was invited to speak at the NIA/NINDS Workshop on Dementia with Lewy Bodies (DLB), where it presented buntanetap's distinctive mechanism of action and its potential as a treatment for DLB. In December 2024, Annovis hosted a year-end webcast, where management addressed key questions from shareholders and provided updates on the Company's clinical progress and upcoming milestones. Financial results Fourth quarter – Research and development expenses for the three months ended December 31, 2024, were $5.0 million compared to $8.9 million for the three months ended December 31, 2023. General and administrative expenses for the three months ended December 31, 2024, were $1.7 million compared to $1.5 million for the three months ended December 31, 2023. Annovis reported a $0.43 basic and diluted net loss per common share for the three months ended December 31, 2024, compared to a $2.24 basic and diluted net loss per common share for the three months ended December 31, 2023. Full year – Research and development expenses for the year ended December 31, 2024, were $20.0 million compared to $38.8 million for the year ended December 31, 2023. General and administrative expenses for the year ended December 31, 2024, were $6.7 million compared to $6.2 million for the year ended December 31, 2023. Annovis reported a $2.02 basic and $2.31 diluted net loss per common share for the year ended December 31, 2024, compared to a $6.23 basic and diluted net loss per common share for the year ended December 31, 2023. Annovis' cash and cash equivalents totaled $10.6 million as of December 31, 2024, compared to $5.8 million as of December 31, 2023. The Company estimates that its current cash and cash equivalents, which also include proceeds from its recent $21.0 million stock offering with ThinkEquity, will enable it to fund its operations into the fourth quarter of 2025. The Company had 14.1 million shares of common stock outstanding as of December 31, 2024 and 19.5 million shares of common stock outstanding after the offering with ThinkEquity. About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under 'Risk Factors' in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA Investor Contact:Alexander Morin, Strategic CommunicationsAnnovis Bioir@ (Tables to follow)ANNOVIS BIO, Sheets(Unaudited) As of December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 10,551,916 $ 5,754,720 Prepaid expenses and other current assets 3,373,717 4,453,544 Total assets $ 13,925,633 $ 10,208,264 Liabilities and stockholders' equity (deficit) Current liabilities: Accounts payable $ 2,305,974 $ 1,292,837 Accrued expenses 1,575,013 2,986,273 Total current liabilities 3,880,987 4,279,110 Non-current liabilities: Warrant liability 737,000 13,680,000 Total liabilities 4,617,987 17,959,110 Commitments and contingencies (Note 6) Stockholders' equity (deficit) : Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 1,414 1,052 Additional paid-in capital 144,155,694 102,507,189 Accumulated deficit (134,849,462 ) (110,259,087 ) Total stockholders' equity (deficit) 9,307,646 (7,750,846 ) Total liabilities and stockholders' equity (deficit) $ 13,925,633 $ 10,208,264 ANNOVIS BIO, of Operations(Unaudited) Three Months Ended Year Ended December 31, December 31, 2024 2023 2024 2023 Operating expenses: Research and development $ 4,998,578 $ 8,904,730 $ 19,995,447 $ 38,790,603 General and administrative 1,736,293 1,537,094 6,699,481 6,244,408 Total operating expenses 6,734,871 10,441,824 26,694,928 45,035,011 Operating loss (6,734,871 ) (10,441,824 ) (26,694,928 ) (45,035,011 ) Other income (expense): Interest income 126,273 66,130 331,849 667,898 Other financing costs 16,939 — (1,853,189 ) — Change in fair value of warrants 727,000 (11,837,200 ) 3,625,893 (11,837,200 ) Total other income (expense), net 870,212 (11,771,070 ) 2,104,553 (11,169,302 ) Net loss $ (5,864,659 ) $ (22,212,894 ) $ (24,590,375 ) $ (56,204,313 ) Net loss per share Basic $ (0.43 ) $ (2.24 ) $ (2.02 ) $ (6.23 ) Diluted $ (0.43 ) $ (2.24 ) $ (2.31 ) $ (6.23 ) Weighted-average number of common shares used in computing net loss per share Basic 13,794,519 9,903,564 12,182,475 9,023,138 Diluted 13,794,519 9,903,564 12,235,444 9,023,138 Sign in to access your portfolio
